Expert Interview
Discussing CRISPR Therapeutics Phase 1 Trial of their CRISPR-Cas9 Gene Editing Treatment, CTX310, Targeting ANGPTL3 and its Potential in Cardiovascular Disease
Ticker(s): CRSPInstitution: Penn Medicine
- Cardiologist affiliated with Penn Medicine / Penn Presbyterian Medical Center and Virtua hospitals in the region.
- Manages 2500 patients with hyperlipidemia
- Serves also as Clinical Associate Professor of Medicine and directs the Penn Cardiology Anticoagulation Clinic in Cherry Hill, combining clinical care, teaching, and specialized cardiovascular management.
How does LB-102’s potential compare to newer entrants like Caplyta (lumateperone) or KarXT (xanomeline/trospium)?
Added By: nick_adminBased on the published data, what do you see as the key strengths of CTX310 (e.g. magnitude of lipid reduction, durability, mechanism, potential impact on cardiovascular risk)?
Added By: nick_adminFrom what you know today, how optimistic are you about the future of in vivo gene editing (such as CTX310) for common diseases such as dyslipidemia or cardiovascular disease?
Added By: nick_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
